Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002172 · ClinicalTrials.gov registry record · NA
An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml
A NA study, sponsored by The Immune Response Corporation.
- Completed
- Registry status
- NA
- Development phase
NCT00002172: Completed NA study, sponsored by The Immune Response Corporation.
NCT00002172 is a NA study that has completed, run by The Immune Response Corporation. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002172, a NA study, has completed, sponsored by The Immune Response Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To provide product through an expanded access program to HIV-infected patients with CD4 counts less than 300 cells/ml.
Interventions
- BIOLOGICAL HIV-1 Immunogen
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002172
The ClinicalTrials.gov registry entry for NCT00002172 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is The Immune Response Corporation, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HIV-1 Immunogen is the first listed.
NCT00002172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002172 about?
NCT00002172 is a clinical study titled "An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml". To provide product through an expanded access program to HIV-infected patients with CD4 counts less than 300 cells/ml.
What is the current status of trial NCT00002172?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002172?
The interventions under investigation include: HIV-1 Immunogen (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002172?
This trial is sponsored by The Immune Response Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.